TIDMYGEN

Yourgene Health PLC

19 May 2021

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Distribution Partnership for the Middle East and Africa

Yourgene and Alliance Global launch partnership across multiple territories

Manchester, UK - 19 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it is launching a Distribution Partnership with Dubai-headquartered Alliance Global FZ LLC ('AGBL' or 'Alliance Global') across a broad range of territories in the Middle East and Africa to expand the Company's geographical footprint and its customer base.

Alliance Global is the largest biomedical gateway in the Middle East, Africa, and Asia and is both a well-respected and a long-term partner for many international and U.S. diagnostics groups looking to pursue a strategy of expansion in these regions. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the regions' emerging healthcare market. AGBL is a well-positioned platform agnostic partner for Yourgene, working with key providers of both PCR and sequencing technologies. AGBL will be focusing on Yourgene's product portfolio of non-invasive prenatal testing ('NIPT'), the reproductive health range including Cystic Fibrosis and QST*R rapid aneuploidy analysis, DPYD genotyping and the new size selection and enrichment technologies, Yourgene QS250 and LightBench(TM).

In response to the restriction on travel to key regions as a result of the COVID-19 pandemic, Yourgene has reviewed it's strategy for bringing products to market in new territories. Following a review of the Company's channels across its international markets, the commitment and focus with a local network in the Middle East and Africa provided by AGBL, is expected to generate future growth opportunities for the Company. AGBL has strong technical expertise to distribute and support Yourgene's growing product range and customer base across these regions, offering an expansive geographic reach and more commercial drivers on the ground to meet the needs of this exciting, emerging international market.

Commenting, Lyn Rees, CEO of Yourgene, said: "This partnership with AGBL is a really exciting progression for Yourgene and our product portfolio as we continue to expand into further territories. AGBL will provide a strong and well positioned channel to allow us to deliver and drive growth for our current and future products. This is a key international market for Yourgene and we look forward to working with AGBL and utilising their expertise to secure further market penetration and geographic expansion."

 
Yourgene Health plc                                               Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                           investors@yourgene-health.com 
Barry Hextall, Chief Financial Officer 
Joanne Cross, Director of Marketing 
 
N+1 Singer (Joint Corporate Broker)                               Tel: +44 (0)20 7496 3000 
Aubrey Powell / Tom Salvesen / George 
 Tzimas 
 
Stifel Nicolaus Europe Limited (Joint                             Tel: +44 (0)20 7710 7600 
 Corporate Broker) 
Nicholas Moore / Matthew Blawat / Ben 
 Maddison 
 
Walbrook PR Ltd (Media and Investor    Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
 Relations) 
 Paul McManus / Lianne Cawthorne                           Mob: 07980 541 893 / Mob: 07584 
                                                                                   391 303 
 
 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASFEFUAEFSEEI

(END) Dow Jones Newswires

May 19, 2021 02:00 ET (06:00 GMT)

Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Yourgene Health Charts.
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Yourgene Health Charts.